BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:13 PM
 | 
Sep 10, 2012
 |  BC Extra  |  Top Story

Geron slides on trial discontinuation

Geron Corp. (NASDAQ:GERN) fell $1.62 (56%) to $1.28 on Monday after discontinuing a Phase II trial of imetelstat to treat locally recurrent or metastatic breast cancer following interim data that showed significantly shorter median progression-free survival in patients receiving imetelstat plus paclitaxel vs. paclitaxel alone (6.2 vs. 8 months, p=0.028). Geron attributed the data to lower doses of paclitaxel given to patients in...

Read the full 297 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >